Skip to main content
. 2021 Jun 2;28(1):1055–1066. doi: 10.1080/10717544.2021.1931560

Figure 3.

Figure 3.

Characterization of HA-P-PEI/siRNA nanoparticles. Gel-retardation assay of PEI/siRNA (A), HA-PEI/siRNA (B) and HA-P-PEI/siRNA (C) at different N/P ratios. TEM and DLS results for the HA-PEI/siRNA (D, G) and HA-P-PEI/siRNA nanoparticles before (E, H) and after (F, I) MMP-2 treatment for 6 h (J) Serum stability of Free siRNA, PEI/siRNA, HA-PEI/siRNA and HA-P-PEI/siRNA.